- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Assertio Therapeutics Inc (ASRT)
Assertio Therapeutics Inc stock price live, this page displays NASDAQ ASRT stock exchange data. View the ASRT premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Assertio Therapeutics Inc real time stock price chart below.
What Is the Assertio Therapeutics Inc Stock Price Today?
The Assertio Therapeutics Inc stock price today is 13.7200.
What Is the Stock Symbol for Assertio Therapeutics Inc?
The stock symbol for Assertio Therapeutics Inc is "ASRT."
What Stock Exchange Does Assertio Therapeutics Inc Trade On?
Assertio Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Assertio Therapeutics Inc a Good Stock to Buy?
Determining whether Assertio Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ASRT quote. (ISIN: US04546C3043)
What Is the Assertio Therapeutics Inc Stock Price Today?
The Assertio Therapeutics Inc stock price today is 13.7200.
What Is the Stock Symbol for Assertio Therapeutics Inc?
The stock symbol for Assertio Therapeutics Inc is "ASRT."
What Stock Exchange Does Assertio Therapeutics Inc Trade On?
Assertio Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Assertio Therapeutics Inc a Good Stock to Buy?
Determining whether Assertio Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ASRT quote. (ISIN: US04546C3043)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
13.2062
13.9000
52 wk Range
7.7055
15.1500
ASRT is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
13.206213.9000
52 wk Range
7.705515.1500
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ASRT Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
38.2500
Upside
+178.79%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
RSI suggests the stock is in overbought territory
- Form 8K Assertio Therapeutics Inc For: 12 January
- Investing.com
- Form 8K Assertio Therapeutics Inc For: 16 March
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Assertio Holdings, Inc., a pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.
Assertio Therapeutics Inc Earnings Call Summary for Q4/2025
- Assertio Q4 2025 EPS of -$1.06 missed forecast of -$0.07 by 1,414%; revenue of $13.5M fell 52% short of $28.4M estimate
- Rolvedon sales plummeted due to inventory timing issues, driving total product sales down 57% YoY to $12.8M from $29.6M
- Gross margin improved to 75% from 61% YoY on favorable sales mix; SG&A expenses decreased 38.8% to $13.1M
- Q1 2026 EPS forecast at -$0.83 with profitability expected in later quarters as Rolvedon sales normalize
- Stock rose 2.08% post-earnings to $11.54 despite miss, reflecting investor confidence in long-term strategy
Last Updated: 03/17/2026, 05:36 AM
Read Full TranscriptCompare ASRT to Peers and Sector
Metrics to compare | ASRT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipASRTPeersSector | |
|---|---|---|---|---|
P/E Ratio | −2.9x | −6.0x | −0.5x | |
PEG Ratio | 0.08 | 0.69 | 0.00 | |
Price/Book | 0.9x | −5.9x | 2.6x | |
Price / LTM Sales | 0.7x | 6.5x | 3.1x | |
Upside (Analyst Target) | 192.4% | 118.9% | 55.6% | |
Fair Value Upside | Unlock | −2.9% | 8.6% | Unlock |
Analyst Ratings
4 Buy
0 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 38.2500
(+178.79% Upside)
Earnings
Latest Release
Mar 16, 2026
EPS / Forecast
-1.06 / -0.07
Revenue / Forecast
13.54M / 28.36M
People Also Watch
FAQ
What Is the Assertio Therapeutics (ASRT) Stock Price Today?
The Assertio Therapeutics stock price today is 13.7200 USD.
What Stock Exchange Does Assertio Therapeutics Trade On?
Assertio Therapeutics is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Assertio Therapeutics?
The stock symbol for Assertio Therapeutics is "ASRT."
What Is the Assertio Therapeutics Market Cap?
As of today, Assertio Therapeutics market cap is 88.0400M USD.
What Is Assertio Therapeutics's Earnings Per Share (TTM)?
The Assertio Therapeutics EPS (TTM) is -4.7439.
When Is the Next Assertio Therapeutics Earnings Date?
Assertio Therapeutics will release its next earnings report on Mar 16, 2026.
From a Technical Analysis Perspective, Is ASRT a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Assertio Therapeutics Stock Split?
Assertio Therapeutics has split 2 times.
How Many Employees Does Assertio Therapeutics Have?
Assertio Therapeutics has 58 employees.
What is the current trading status of Assertio Therapeutics (ASRT)?
As of Mar 20, 2026, Assertio Therapeutics (ASRT) is trading at a price of 13.7200 USD, with a previous close of 13.6800 USD. The stock has fluctuated within a day range of 13.2062 USD to 13.9000 USD, while its 52-week range spans from 7.7055 USD to 15.1500 USD.
What Is Assertio Therapeutics (ASRT) Price Target According to Analysts?
The average 12-month price target for Assertio Therapeutics is 38.2500 USD, with a high estimate of 45 USD and a low estimate of 28 USD. 4 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +178.79% Upside potential.
What Is the ASRT Premarket Price?
ASRT's last pre-market stock price is 13.5900 USD. The pre-market share volume is 578.0000, and the stock has decreased by -0.0900, or -0.6600%.
What Is the ASRT After Hours Price?
ASRT's last after hours stock price is 13.9501 USD, the stock has decreased by 0.2301, or 1.6800%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.